Combined Hepatocellular Cholangiocarcinomas; Analysis of a Large Database

Department of Pathology.
Clinical Medicine: Pathology 03/2008; 1:43-7.
Source: PubMed

ABSTRACT Combined hepatocellular cholangiocarcinoma (combined tumor) has been described as either a variant of hepatoma or a variant of cholangiocarcinoma. Prior studies evaluated fewer than 50 patients with combined tumors, precluding multivariate analyses. Posited was the notion that analysis of a large database would yield more definite answers.
This study used SEER (Surveillance, Epidemiology, and End Results Program of the National Cancer Institute) to analyze 282 combined tumors, 2,035 intrahepatic cholangiocarcinomas, and 19,336 hepatomas between the years 1973-2003. Multinomial logit regression calculated point estimates and 95% confidence intervals (c.i.) for relative risk (rr). Cox regression calculated point estimates and 95% confidence intervals (c.i.) for hazard ratios (ĥ).
Men less often had cholangiocarcinomas than they had combined tumors (rr = 0.63, c.i. = 0.49-0.81). Hepatomas less often than combined tumors presented with distant spread (rr = 0.56, c.i. = 0.43-0.72). Men (rr = 1.50, c.i. = 1.17-1.93) and patients with a known Asian or Pacific birthplace (rr = 2.36, c.i. = 1.56-3.56) more often had hepatomas than they had combined tumors. Among patients not known to have an Asian/Pacific birthplace, a diagnosis of cholangiocarcinoma (ĥ = 0.72, c.i. = 0.63-0.82) or hepatoma (ĥ = 0.75, c.i. = 0.66-0.86) provided a better prognosis than did a diagnosis of combined tumor.
Combined tumors differ from hepatomas and cholangiocarcinomas in terms of distribution and survival patterns in the population; they should be considered neither cholangiocarcinomas nor hepatomas.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Combined Hepatocellular-cholangiocarcinoma (cHCC-CC) is a rare primary liver cancer. Aims were to analyze cHCC-CC demographic, clinical, and pathologic characteristics at a population level, and to investigate the effects of these features as well as different management strategies on prognosis.Methods: The Surveillance, Epidemiology, and End Results (SEER) database was analyzed between 1988 and 2009. Data analyses were performed utilizing chi-square tests, ANOVA, Kaplan-Meier curves, and Cox proportional hazards regression.Results: A total of 467 patients with cHCC-CC, 52825 patients with HCC, and 7181 patients with CC were identified. cHCC-CC was more common in patients who were white, male, and older than 65 years. Treatment was more frequently non-surgical/interventional. cHCC-CC, HCC, and CC had 5-year overall and disease-specific survival rates of 10.5, 11.7, and 5.7% (p<0.001), and 17.8, 21.0 and 11.9% (p<0.001), respectively. For cHCC-CC patients, increasing invasivity of therapeutic approach was significantly associated with prolonged survival (P<0.0001). In the multivariate model, black race, distant SEER stage, and tumor size 5-10 cm were independently associated with lower survival in cHCC-CC patients; year of diagnosis after 1996, and surgical treatment with minor and major hepatectomy and liver transplantation were independently associated with better survival in cHCC-CC patients. Patients diagnosed with cHCC-CC, HCC and CC and treated with liver transplantation had respectively a 5-years OS of 41.1%, 67.0% and 29.0% (p <0.001).Conclusions: cHCC-CC appears to show intermediate demographic, clinical, and survival characteristics of HCC and CC. Liver transplantation in cHCC-CC patients showed inferior survival compared to HCC, and the role and indications for liver transplantation in cHCC-CC have yet to be defined. Up to date, major hepatectomy may be considered the best therapeutic approach for such patients. Liver Transpl , 2014. © 2014 AASLD.
    Liver Transplantation 08/2014; 20(8). DOI:10.1002/lt.23897 · 3.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND AND OBJECTIVES: Although transplantation has demonstrated survival benefit for patients with hepatocellular carcinoma (HCC), there is limited data to support or refute transplantation for combined hepatocellular-cholangiocarcinoma (cHCC-CC). We hypothesized that cHCC-CC patients had poorer overall survival (OS) than HCC patients after liver transplantation. METHODS: Patients with localized HCC and cHCC-CC treated with surgical resection or transplant were identified using the Surveillance, Epidemiology, and End Results (SEER) Database (1973-2007). Cox proportional hazards models were used to examine survival. RESULTS: We identified 3,378 (1,447 [43%] transplant, 1,931 [57%] resection) patients with HCC, and 54 (19 [35%] transplant, 35 [65%] resection) patients with cHCC-CC. Patients undergoing resection of HCC and cHCC-CC had similar 3-year OS (55% vs. 46%, P = 0.4). Three-year OS of patients undergoing transplant was significantly greater for HCC (78%) than for cHCC-CC (48%, P = 0.01). In adjusted models, patients transplanted for cHCC-CC had higher hazard of death compared to HCC patients (HR 2.5, 95% CI: 1.2-5.1, P = 0.01). CONCLUSIONS: Transplantation for localized cHCC-CC confers a survival benefit similar to liver resection for cHCC-CC, but inferior to transplantation for HCC. With survival data that mimics historic reports of transplant for intrahepatic cholangiocarcinoma, this study questions the benefit of transplantation for patients with cHCC-CC. J. Surg. Oncol © 2013 Wiley Periodicals, Inc.
    Journal of Surgical Oncology 05/2013; 107(6). DOI:10.1002/jso.23289 · 2.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE. The purpose of this study was to evaluate the diagnostic accuracy of preoperative imaging for diagnosis of combined hepatocellular cholangiocarcinoma tumors and to evaluate the clinical and imaging features and demographics of patients presenting to our institution with such tumors. MATERIALS AND METHODS. From January 2001 to January 2011, 29 patients presented with pathologically proven combined hepatocellular cholangiocarcinoma tumors to our institution. A retrospective review of the imaging studies, clinical data, and demographic information in these patients was conducted. Two radiologists with 6 and 18 years of experience reviewed the imaging studies of patients with combined hepatocellular cholangiocarcinoma tumors and matched control cases of hepatocellular carcinoma (HCC) (n = 15) and cholangiocarcinoma (n = 18). The reviewers were blinded to the pathologic diagnosis. Imaging features on contrast-enhanced MRI and CT with the suggested final diagnosis were recorded. RESULTS. The demographics of our patient population were similar to other reported U.S. populations, with cirrhosis and hepatitis present in a minority of patients. The imaging features of combined hepatocellular cholangiocarcinoma tumors overlapped with those of HCC and cholangiocarcinoma. The correct diagnosis of combined hepatocellular cholangiocarcinoma tumors was made in a minority of cases by either radiologist, with misdiagnosis more often leading to suggestion of cholangiocarcinoma than HCC. Sensitivities and specificities for diagnosis of combined hepatocellular cholangiocarcinoma tumors ranged from 33% to 34% and 81% to 100%, respectively. CONCLUSION. Preoperative diagnosis of combined hepatocellular cholangiocarcinoma tumors on the basis of imaging features is accurate in the minority of cases. Tumor markers and risk factors may help improve accuracy; however, in the absence of classic imaging features and supportive information for HCC or cholangiocarcinoma, biopsy should be considered for confirmation of diagnosis.
    American Journal of Roentgenology 08/2013; 201(2):332-9. DOI:10.2214/AJR.12.9488 · 2.74 Impact Factor


1 Download
Available from